Edition:
United Kingdom

People: Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

18.08USD
19 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$18.08
Open
--
Day's High
--
Day's Low
--
Volume
3,020
Avg. Vol
1,717,029
52-wk High
$23.91
52-wk Low
$2.36

Farrell, Michael 

Michael J. Farrell is Vice President - Finance (principal accounting officer and principal financial officer) of Amarin Corp Plc. Prior to joining Amarin, Mr. Farrell spent the previous ten years with various life sciences companies. From May 2012 to June 2013, Mr. Farrell was the Controller for Unigene Laboratories, Inc., a publicly traded biotechnology company, where he was responsible for the accounting and finance function, which included a significant role in multiple financing transactions. From October 2010 to April 2012, he was the Controller of New American Therapeutics, Inc., where he contributed to the formation of the company and the successful acquisition and subsequent divestiture of the company’s assets. From April 2008 to September 2010, he was Controller of Akrimax Pharmaceuticals LLC. From April 2004 through March 2008, he held various roles of increasing responsibility within the finance department at Reliant Pharmaceuticals, Inc. prior to the sale of the company to GlaxoSmithKline. Mr. Farrell started his career at Arthur Andersen LLP in 1999, during which time he became a Certified Public Accountant. Mr. Farrell holds a B.S. in Accounting from the University of Maryland.

Basic Compensation

Total Annual Compensation, USD 240,719
Restricted Stock Award, USD 39,780
Long-Term Incentive Plans, USD --
All Other, USD 70,775
Fiscal Year Total, USD 351,274

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Lars Ekman

--

John Thero

2,769,490

Michael Kalb

--

Stephen Ketchum

1,198,590

Joseph Kennedy

1,201,640

Aaron Berg

--
As Of  31 Dec 2014